In today’s evolving regulatory landscape, medical device manufacturers and operators must pay close attention to their post-market surveillance and vigilance obligations.
The EU Medical Device Regulation (MDR – Regulation (EU) 2017/745) has introduced a much stricter framework governing device lifespan, performance, and real-world feedback collection.
For BluePharm and its partners, this is a strategic priority — not only to maintain regulatory compliance, but also to reinforce product safety, reliability, and brand reputation in the European market.
The regulatory framework for post-market surveillance and vigilance
Chapter VII of the MDR (Regulation 2017/745) defines a comprehensive framework for post-market surveillance and vigilance.
In practical terms, this includes:
- Establishing a PMS system as part of the manufacturer’s quality management system (QMS);
- Reporting all serious incidents and implementing Field Safety Corrective Actions (FSCA) when necessary;
- Preparing Periodic Safety Update Reports (PSURs) or Post-Market Surveillance Reports (PMSR), depending on the device risk class;
- Performing trend analysis to detect and prevent potential failures.
In essence, vigilance and PMS create a continuous improvement loop — collecting data, analyzing it, taking corrective action, and documenting outcomes.
More information: European Commission – Medical Devices Regulation.
Understanding PMS, PMSR, and PSUR: the foundation of post-market surveillance
These acronyms form the backbone of the EU’s post-market surveillance system for medical devices.
1. PMS – Post-Market Surveillance
The PMS system is the overarching process implemented by the manufacturer to monitor the safety, performance, and compliance of a device throughout its lifecycle.
It relies on continuous data collection — incident reports, user feedback, clinical follow-up studies — to identify risks early and take preventive or corrective action.
2. PMSR – Post-Market Surveillance Report
The PMSR is a simplified report, primarily required for Class I devices (and some low-risk Class IIa devices).
It summarizes PMS data, key safety and performance findings, and must be kept available for competent authorities, updated as necessary when new findings arise.
3. PSUR – Periodic Safety Update Report
The PSUR applies to Class IIa, IIb, and III devices and provides a more detailed overview, including:
- Benefit-risk assessment,
- Incident trends and corrective actions,
- Performance and safety summaries.
Frequency: every two years for Class IIa devices and annually for Class IIb and III devices.
Further details: MDCG – Guidance on PMS and vigilance under MDR/IVDR.
Why strengthen vigilance and post-market surveillance?
Several factors explain why PMS and vigilance have become critical:
- Faster technological evolution (software, connected devices, complex implants) introduces new and evolving risks;
- Regulatory expectations from European authorities have tightened — demanding more data, transparency, and periodic reviews;
- Market perception has changed: proactive vigilance builds user confidence, reduces recall costs, and enhances brand value;
- Non-compliance can now result in market withdrawals, financial penalties, or even legal liability.
Effective vigilance is therefore both a compliance requirement and a competitive advantage.
Best practices to anticipate and structure medical device vigilance
Here are five essential practices to strengthen vigilance and post-market monitoring:
a. Integrate vigilance from the design phase
From the earliest development stages, manufacturers should plan for post-launch data collection and implement a PMS/PMSR/PSUR plan. Medical writing plays a key role in preparing documentation for the technical file and associated reports.
b. Implement efficient trend analysis
Vigilance is not just reactive. Monitoring incident frequency, usage patterns, and performance drift helps anticipate product deviations before they escalate.
c. Develop structured PSUR documentation
For Class IIa, IIb, III, and implantable devices, periodic PSUR or PMS reports are mandatory. Manufacturers should plan key indicators, establish standardized review processes, and align reports with risk classification.
d. Align documentation, quality, and traceability
The PMS system must be integrated into the QMS, ensuring that economic operators — manufacturers, authorized representatives, and distributors — are clearly identified and traceable.
e. Communicate corrective measures effectively
When serious incidents occur, authorities must be notified, and users informed through Field Safety Notices (FSN) or other corrective actions.
In short: vigilance must be proactive, documented, and strategically aligned with product and market goals.
Additional resource: ANSM – Post-market surveillance and vigilance (France).
Implications for manufacturers, and partners like BluePharm
For manufacturers
- Increased documentation obligations leading to heavier reporting workloads;
- Need to anticipate user feedback and integrate it into ongoing product strategy;
- Higher non-compliance risk, reinforcing the value of expert regulatory support.
For partners like BluePharm
- Support in data collection and structuring for PMS/PSUR reports;
- Preparation of periodic safety documentation and Field Safety Notices (FSN);
- Strategic consulting on traceability, post-market performance indicators, and compliance optimization.
By combining regulatory expertise with clinical and editorial experience, BluePharm helps manufacturers turn PMS compliance into a driver of continuous improvement and market trust.
Conclusion: vigilance as a lever for safety and competitiveness
Post-market surveillance and vigilance for medical devices are no longer optional — they are now at the heart of both regulatory compliance and product performance.
By adopting a structured, proactive, and MDR-aligned approach, manufacturers can transform vigilance from a legal obligation into a strategic asset.
With its expertise in medical writing, data analysis, and PMS reporting, BluePharm supports the industry in meeting these new European standards efficiently and transparently.
